We are a privately held medical device company developing a novel, rapid-acting brain stimulation technology designed to treat people suffering from major depressive disorder (MDD) who have not responded to existing treatments.
RESTORING MENTAL HEALTH.
Depression is caused by identifiable changes in brain networks.
We can restore healthy neural activity and relieve symptoms of depression.
Breakthrough technology. Advanced imaging, individualized targeting, and novel stimulation patterns yield a new approach to personalized neurostimulation for people with treatment-resistant depression.
25+ years’ driving organizational and commercial impact with Fortune 500 and healthcare startups. Previously CCO for iRhythm Technologies, Inc., VP of U.S. Sales at InTouch Health, and Area VP at Intuitive Surgical. Extensive international experience leading business units for Fortune 500 healthcare companies.
Previously CEO and co-founder of Halo Neuroscience. 20 years of neuromodulation industry experience. NeuroPace and ATI alumnus, former principal engineer and clinical scientist. Registered patent agent and prolific inventor with 60+ US patents.
25 years’ experience in planning and executing clinical trials to support approval of class II and class III medical devices in a variety of therapeutic areas at both startups and large companies. Previously VP of Clinical Affairs at Radial Medical and Halo Neuroscience; in-depth clinical affairs experience at Gynesonics, Abbott Vascular and Bailer Research.
20+ years’ experience in market access and reimbursement, marketing, and market development in the medical device industry. Previously EVP of Marketing at Elixir Medical and VP of Market Access at Heartflow; held multiple leadership positions at Abbott Vascular in Market Access and Marketing.
15+ year career specializing in start-up commercialization for medical device companies. Previously Vice President, Commercial Enablement at iRhythm Technologies. Additional start-up experience in sales and training for CardioDx and ThermoFishcer Scientific, now PhadiaAB, Merz Pharmaceuticals, and Schering-Plough.
40+ years’ experience in the healthcare industry recognized for extensive knowledge of hospital-based and ambulatory care delivery systems in academic medicine. Previously held numerous executive positions with Stanford Health Care, including within the Department of Psychiatry and Behavioral Sciences, most recently as Vice President for Business Development.
Previously Partner, Managing Director, and Life Sciences Investment Team Leader in TPG’s Biotech, Growth and RISE platforms; co-founder and Partner at Novo Ventures’ San Francisco office; Managing Director at Piper Jaffray Ventures; co-founder and CEO of AutoMate Scientific. Led multiple investments with successful exits, including Amira, AnaptysBio, Cianna Medical, Engage Therapeutics, Elevation Pharma, Flexion, FoldRx, Spinifex and Vaxcyte. Currently chairman of publicly traded companies Inogen and Satsuma Pharmaceuticals. McKinsey alumnus with PhD in neuroscience from Stanford.
Deep experience in venture capital investment, company building, technology development, and neurosurgery. Previous partner at Flare Capital Partners and principal at Canaan Partners; founder and key inventor of Northstar Neuroscience (IPO in 2006, subsequently acquired by St. Jude Medical); was chairman of IntElect Medical (acquired by Boston Scientific). Led investments with successful exit and held board seats at BridgePoint Medical, Explorys, Eyefluence, Visiogen, and more. Board-certified neurosurgeon with over 50 medical articles and numerous patents.